Edition:
India

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

26.32USD
24 Nov 2017
Change (% chg)

$2.83 (+12.05%)
Prev Close
$23.49
Open
$24.06
Day's High
$26.32
Day's Low
$24.06
Volume
413,457
Avg. Vol
299,760
52-wk High
$32.22
52-wk Low
$15.98

Summary

Name Age Since Current Position

Patrick Mahaffy

54 2009 Chairman of the Board

Michael Clayman

65 President, Chief Executive Officer, Co-Founder, Director

Neil Bodick

70 2017 Chief Scientific Officer

Mark Levine

43 2017 Vice President, General Counsel

John Magee

2016 Vice President - Sales

Mark Fraga

2017 Vice President - Marketing

Scott Kelley

2017 Vice President - Medical Affairs

Dan Thornton

2017 Vice President - Market Access

Yamo Deniz

52 2017 Chief Medical Officer

Mark Stejbach

53 2016 Director

Scott Canute

57 2015 Independent Director

Samuel Colella

77 2008 Independent Director

Heath Lukatch

50 2012 Independent Director

Sandesh Mahatme

52 2014 Independent Director

Ann Merrifield

66 2014 Independent Director

Alan Milinazzo

57 2011 Independent Director

Biographies

Name Description

Patrick Mahaffy

Mr. Patrick Mahaffy serves as Chairman of the Board of Flexion Therapeutics, Inc. Mr. Mahaffy has served as the President, Chief Executive Officer, and a director of Clovis Oncology, Inc., a biopharmaceutical company, since 2009, and also serves on the board of directors of Orexigen Therapeutics, Inc., a biopharmaceutical company. Previously, Mr. Mahaffy served as President and Chief Executive Officer and as a member of the board of directors at Pharmion Corporation, a pharmaceutical company that he founded in 2000 and sold to Celgene Corporation in 2008. From 1992 through 1998, Mr. Mahaffy was President and Chief Executive Officer of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals, Inc., a biopharmaceutical company. Prior to that, Mr. Mahaffy was a Vice President at the private equity firm E.M. Warburg Pincus and Co. He is also a trustee of Lewis and Clark College.

Michael Clayman

Dr. Michael Clayman, M.D. serves as the Chief Executive Officer, Co-Founder, President and Board Member of Flexion Therapeutics, Inc. Dr. Clayman also serves on the board of directors of Akebia Therapeutics, Inc., a biopharmaceutical company. Previously, Dr. Clayman had a lengthy career at Eli Lilly and Company, a global pharmaceutical company, where he was most recently Vice President, Lilly Research Laboratories, and General Manager of Chorus, Lilly’s early-phase development accelerator. During his career at Lilly, Dr. Clayman also led its Global Regulatory Affairs division, the Cardiovascular Discovery Research and Clinical Investigation, Research and Development at Advanced Cardiovascular Systems, a medical device subsidiary of Lilly, the Internal Medicine Division, the Lilly Clinic, Lilly’s dedicated Phase 1 unit, and served as Chair of Lilly’s Bioethics Committee. Prior to his tenure at Lilly, Dr. Clayman was an Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the immunopathogenesis of renal disease. Dr. Clayman is the recipient of the Physician Scientist Award from the National Institutes of Health.

Neil Bodick

Dr. Neil Bodick, M.D., Ph.D. serves as Chief Scientific Officer of the Company. He was Chief Medical Officer of Flexion Therapeutics, Inc. Previously, Dr. Bodick was at Eli Lilly and Company, where he founded Chorus and served as Chief Medical Officer and Chief Operating Officer. Prior to that, Dr. Bodick was responsible for early-phase clinical investigation at Lilly Research Laboratories. He also was Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the development of computer-based systems to support image-intensive diagnosis. Dr. Bodick holds 13 patents in the areas of neuroscience and computer science and is the recipient of the Biomedical Research Service Award and the New Investigator Research Award from the National Institutes of Health.

Mark Levine

Mr. Mark Levine serves as General Counsel, Secretary of the company. Mark Levine has more than twenty years of experience counseling companies on general corporate matters, including: strategic corporate development; complex commercial transactions; mergers, acquisitions and divestitures; licensing agreements and corporate partnerships; financings; securities law; corporate governance; and regulatory compliance. Prior to joining Flexion, Mr. Levine served as Senior Vice President, General Counsel and Corporate Secretary and a member of the executive management team of Minerva Neurosciences, Inc., a publicly traded biotechnology company. Mr. Levine has also served in senior legal positions at athenahealth, Inc., a network-based health internet technology company; Clinical Data, Inc., a biopharmaceutical company acquired by Forest Laboratories, Inc.; Wheelabrator Technologies Inc., a renewable energy company; and Xpedior Incorporated, an internet consulting company. Mr. Levine holds a bachelor of arts degree from Binghamton University, SUNY, and a juris doctor degree from Washington University School of Law in St. Louis.

John Magee

Mr. John Magee serves as Vice President - Sales of the Company. Mr. Magee has more than 35 years of experience as a sales professional and brings extensive experience in successfully recruiting and managing pharmaceutical sales organizations. Prior to joining Flexion, he was head of U.S. sales for the rare disease unit of Shire Pharmaceuticals, where he also served as U.S. sales director for its renal business. During his time in the rare disease unit of Shire, he helped to achieve revenue growth of more than $1 billion. Previously, he held senior sales positions at Esprit Pharma and Bayer Corporation. He has a Bachelor’s degree in biology and anthropology from Hamilton College, and completed MBA courses at the Rochester Institute of Technology.

Mark Fraga

Scott Kelley

Dr. Scott Kelley serves as Vice President - Medical Affairs of the company. Dr. Kelley has over 25 years of clinical, academic and industry medical affairs experience. Most recently, Dr. Kelley served as Vice President, Global Medical Affairs at Sanofi where he oversaw global data generation, data dissemination and KOL engagement strategy for the Biosurgery portfolio including Synvisc®, an injectable product for osteoarthritis of the knee. Prior to Sanofi, Dr. Kelley led medical affairs functions at Covidien Respiratory & Monitoring Solutions and at Aspect Medical Systems. Dr. Kelley earned his BS and MS from Stanford University and his MD from University of California, San Francisco. He completed his residency and fellowship in Anesthesiology at UCSF and obtained board certifications in Anesthesiology and Pain Management. Dr. Kelley maintains a clinical practice at Brigham & Women’s Hospital.

Dan Thornton

Mr. Dan Thornton serves as Vice President - Market Access of the company. Mr. Thornton has had leadership roles for nearly 20 years in patient and market access, pricing and distribution, and market development for a number of biotechnology and pharmaceutical firms. Most recently, he was VP of market access and patient services at Chiasma, where he built a comprehensive patient services and market access organization for the launch of an oral product for the treatment of acromegaly. He has also built and executed market access strategies at a number of companies including Shire Pharmaceuticals, Santhera Pharmaceuticals and Targanta Therapeutics. Mr. Thornton earned his BA from Duke University and his MBA from the Wharton School at the University of Pennsylvania.

Yamo Deniz

Dr. Yamo Deniz, M.D. serves as Chief Medical Officer of the Company. Dr. Deniz previously served as the Vice President and Head of Global Medical Affairs for Rare Diseases at Sanofi-Genzyme from 2013 until joining us in 2017. Prior to that, Dr. Deniz was employed by GE Healthcare from 2010 to 2013, where Dr. Deniz served in various roles, including serving as the Vice President and Global Head of Development at GE Healthcare Medical Diagnostics as well as the Chief Medical Officer, Global Head of Medical & Pharmacovigilance at GE Healthcare Life Sciences. Prior to his time at GE Healthcare, Dr. Deniz held numerous senior clinical development positions and leadership roles of increasing responsibility in the Respiratory and Inflammation groups at Genentech and Roche Pharmaceuticals, respectively. Dr. Deniz earned an B.A. in chemistry from the College of the Holy Cross and an M.D. from the University of Massachusetts Medical School. Following an internship and residency in Pediatrics at the Long Island Jewish Medical Center, Dr. Deniz completed a fellowship in Pediatric Allergy and Immunology at Duke University Medical Center.

Mark Stejbach

Mr. Mark P. Stejbach serves as Director of the Company. Mr. Stejbach currently serves as Senior Vice President and Chief Commercial Officer at Alkermes plc, a publicly traded global biopharmaceutical company. Mr. Stejbach has 30 years of experience in biotech and pharmaceuticals, including senior roles in a broad range of commercial functions including marketing, sales, economic affairs, managed care and finance. Prior to his current role, Mr. Stejbach served as the Chief Commercial Officer at Tengion, Inc. from 2008 to 2012 and previously held senior positions at Merck and Biogen. Mark received his M.B.A. from the Wharton School, University of Pennsylvania and a B.S. in mathematics from Virginia Tech. Our Board believes that Mr. Stejbach’s executive and operational experience in the pharmaceutical industry and commercial expertise qualifies him to serve on our Board of Directors.

Scott Canute

Mr. Scott A. Canute serves as Independent Director of Flexion Therapeutics, Inc. since March 4, 2015. Mr. Canute served as President of Global Manufacturing and Corporate Operations at Genzyme Corporation from 2010 to 2011. Prior to joining Genzyme, Mr. Canute spent 25 years at Eli Lilly and Company and served as President, Global Manufacturing Operations from 2004 to 2007. Mr. Canute currently serves as a member of the board of directors of Proteon Therapeutics, a biopharmaceutical company focused on renal and vascular disease. Mr. Canute also serves on the board of directors of Oncobiologics, Inc., a publicly traded biopharmaceutical company focused on developing, manufacturing and commercializing biosimilars, and on the board of directors of Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company focused on renal disease. Mr. Canute previously served as a member of the board of directors of AlloCure, Inc., Inspiration Biopharmaceuticals, Inc., the National Association of Manufacturers and the Indiana Manufacturers Association. Mr. Canute earned a B.S. in chemical engineering from the University of Michigan and an M.B.A. from Harvard Business School. Our Board believes that Mr. Canute’s manufacturing and operational experience in the biopharmaceutical industry and his experience of serving on the board of directors for several biopharmaceuticals companies qualifies Mr. Canute to serve on our Board of Directors.

Samuel Colella

Mr. Samuel D. Colella serves as Independent Director of Flexion Therapeutics, Inc. Mr. Colella is a Managing Director of Versant Ventures, a healthcare venture capital firm he co-founded in 1999, and has been a general partner of Institutional Venture Partners since 1984. Mr. Colella currently serves as Chairman of the board of directors of Fluidigm Corporation, a biotechnology tools company, and is a member of the board of directors of several private companies. Mr. Colella served on the board of directors of Genomic Health, Inc., a molecular diagnostics company, from 2001 to 2014, Alexza Pharmaceuticals, Inc., a pharmaceutical company, from 2002 to 2012, Jazz Pharmaceuticals, Inc., a biopharmaceutical company, from 2003 to 2012 and Veracyte, Inc., a molecular diagnostics company, from 2006 to 2014. Mr. Colella earned a B.S. in business and engineering from the University of Pittsburgh and an M.B.A. from Stanford University. Our Board believes that Mr. Colella’s broad understanding of the life science industry and his extensive experience in working with emerging private and public companies qualifies him to serve on our Board of Directors.

Heath Lukatch

Dr. Heath Lukatch serves as Independent Director of Flexion Therapeutics, Inc. Through April, 30, 2015, Dr. Lukatch will be employed as a Partner at Novo Ventures (US) Inc. which provides certain consultancy services to Novo A/S, a Danish limited liability company that manages investments and financial assets. Dr. Lukatch joined Novo Ventures (US) Inc. in 2006. He currently serves as Chairman of the board of directors of Inogen, Inc., a publicly traded medical technology company. He is also currently a member of the board of directors of a number of private companies. Prior to joining Novo Ventures (US) Inc., Dr. Lukatch was a Managing Director responsible for biotechnology venture investments at Piper Jaffray Ventures and SightLine Partners, a private equity firm and spin off of Piper Jaffray Ventures, from 2001 to 2006. Prior to joining Piper Jaffray Ventures, Dr. Lukatch worked as a strategy consultant with McKinsey & Company, a consulting firm. Dr. Lukatch also served as co-founder and chief executive officer of AutoMate Scientific, Inc. a biotechnology instrumentation company and held scientific positions with Chiron Corporation, a biotechnology company, Roche Bioscience, a healthcare company, and Cetus Corporation, a biotechnology company.

Sandesh Mahatme

Mr. Sandesh (Sandy) Mahatme serves as Independent Director of Flexion Therapeutics, Inc. Since November 2012, Mr. Mahatme has served as Senior Vice President and Chief Financial Officer at Sarepta Therapeutics, Inc., a publicly traded biopharmaceutical company. From January 2006 to November 2012, Mr. Mahatme worked at Celgene Corporation, a publicly traded biopharmaceutical company, where he served in various roles, including Senior Vice President of Corporate Development, Senior Vice President of Finance, Corporate Treasurer and Head of Tax. While at Celgene, Mr. Mahatme built the treasury and tax functions before establishing the Corporate Development Department, focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions, licensing and global manufacturing expansion. From 1997 to 2005 Mr. Mahatme worked for Pfizer Inc., a pharmaceutical company, where he served in senior roles in business development and corporate tax. Mr. Mahatme started his career at Ernst & Young LLP where he advised multinational corporations on a broad range of transactions. Mr. Mahatme also serves on the board of directors of Aeglea Biotherapeutics, Inc., a publicly traded biotechnology company focused on treatments for cancer and certain genetic diseases. Mr. Mahatme earned LL.M. degrees from Cornell Law School and NYU School of Law and is a member of the New York State Bar Association. Our Board believes that Mr. Mahatme’s financial expertise qualifies him to serve on our Board of Directors.

Ann Merrifield

Ms. Ann Merrifield serves as Independent Director of Flexion Therapeutics, Inc. From December 2012 to July 2014, Ms. Merrifield served as President and Chief Executive Officer of PathoGenetix, Inc., a privately held health technology company, which voluntarily filed for Chapter 7 bankruptcy in July 2014. Prior to joining PathoGenetix, Inc., Ms. Merrifield served an 18-year tenure at Genzyme Corporation (now owned by Sanofi S.A.), a diversified, global biotechnology company. At Genzyme, Ms. Merrifield served most recently as President of Genzyme Biosurgery, where she led global business strategy across a portfolio of biologics, therapeutic devices and combination products, and was previously Vice President of Marketing, General Manager and President of Genzyme Genetics, where she played an instrumental role in developing and shaping its diagnostic business. Prior to joining Genzyme, Ms. Merrifield was a Partner at Bain and Company, a global strategy consulting firm, and an Investment Officer at Aetna Life & Casualty. She currently serves as a director of InVivo Therapeutics Holdings Corp., a publicly traded biotechnology company, and as a trustee of MassMutual Premier, Select and MML Series Investment Funds.

Alan Milinazzo

Mr. Alan W. Milinazzo serves as Independent Director of Flexion Therapeutics, Inc., since 2011. Mr. Milinazzo is a partner in the Global Healthcare and Life Sciences Practice at Heidrick & Struggles International, Inc., a global executive search and leadership consulting firm, a position he has held since January 2016. Prior to then, from 2013 to 2016, he served as President, Chief Executive Officer and a member of the board of directors of InspireMD, Inc., a publicly traded medical device company. From 2006 to 2011, Mr. Milinazzo served as president and chief executive officer of Orthofix International, N.V., a publicly traded global orthopedic company, a position he was promoted to in 2006 after initially being hired as the company’s chief operating officer in 2005. From 2002 to 2005, Mr. Milinazzo served as the General Manager of Medtronic, Inc.’s coronary and peripheral vascular businesses. He currently serves on the board of directors of CAS Medical Systems, Inc. (CASMED), a publicly traded medical technology company. Mr. Milinazzo formerly served on the boards of LDR Holding Corporation, a publicly traded medical device company, from 2015 until its acquisition by Zimmer Biomet Holdings in June 2016 and Orthofix International, N.V. from December 2006 until June 2012. He received his undergraduate degree from Boston College. Our Board of Directors believes that Mr. Milinazzo’s expertise in management and marketing in the pharmaceutical and medical device market and his 25 years of experience in the healthcare and life sciences sector qualifies him to serve on our Board of Directors.

Basic Compensation